Latest Earnings Results: Q3 '26
Estimated EPS
$0.74
Reported EPS
$0.80
Surprise
+8.6%
Estimated Rev
$1.68B
Reported Rev
$1.72B
Surprise
+2.33%
• Reported GAAP EPS of $0.80 up 19.40% YoY • Reported revenue of $1.72B up 10.53% YoY • Edwards Lifesciences expects approximately $45M of additional Pillar Two tax expense in 2026 before current-law offsets; UTPR tax expense will be reduced as countries enact the Side-by-Side Safe Harbour.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | $0.66 | -- | -- | N/A |
Q3 '26 | $0.74 | $0.80 | 8.60% | BEAT |
Q2 '26 | $0.74 | $0.78 | 4.97% | BEAT |
Q1 '26 | $0.73 | $0.78 | 6.98% | BEAT |
Q4 '25 | $0.62 | $0.58 | -6.36% | MISSED |